The Dawning of the Age of JUPITER?

Once again, a statin was clearly effective for primary prevention of cardiovascular events, but using CRP levels to determine treatment thresholds remains debatable.

High-sensitivity C-reactive protein, a biomarker of inflammation, independently predicts cardiovascular events. To find out whether treatment with rosuvastatin might decrease the rate of first major cardiovascular events in apparently healthy individuals, investigators for the manufacturer-sponsored Justification for the Use of Statins in Prevention: an Interventional Trial Evaluating Rosuvastatin (JUPITER) studied subjects who had high-sensitivity CRP levels ≥2 mg/L but not high cholesterol levels (LDL levels <130 mg/dL). Of 89,890 men and women who were screened for enrollment, 17,802 were randomly assigned to receive rosuvastatin (20 mg daily) or placebo. The trial was stopped after a median follow-up of 1.9 years when the data and safet…

Reviewing Author

Joel M. Gore, MD

Disclosures

Grant/Research SupportNIH–National Heart, Lung, and Blood Institute

Joel M. Gore, MD

Disclosures

Grant/Research SupportNIH–National Heart, Lung, and Blood Institute

The Dawning of the Age of JUPITER?

Topics

Reviewing Author